The oral-to-intravenous equianalgesic ratio of morphine based on plasma concentrations of morphine and metabolites in advanced cancer patients receiving chronic morphine treatment
Restricted accessResearch articleFirst published online December, 2003
The oral-to-intravenous equianalgesic ratio of morphine based on plasma concentrations of morphine and metabolites in advanced cancer patients receiving chronic morphine treatment
To provide additional pharmacokinetic evidence for the oral-to-parenteral relative potency ratio of 1:2 to 1:3 for chronic morphine use in a palliative care setting, we determined the plasma concentrations of morphine and its major metabolites, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G), in hospitalized advanced cancer patients maintained on long-term oral or intravenous morphine. There were significant linear correlations between daily doses of morphine and plasma concentrations (molar base) of morphine, M3G and M6G for both routes of administration. The oral-to-intravenous relative ratios of the regression coefficients were 2.9 for morphine and 1.8 for morphine» / M6G. The morphine kinetic variables were not significantly influenced by any hepato-renal biochemical markers. These results support the commonly used oral-to-intravenous relative potency ratio of 1:2 to 1:3 in patients with cancer pain receiving chronic morphine treatment.
Zech DFJ, Grond S, Ivyneh J, et al. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain1995; 63: 65–76.
2.
Stjernswärd, J Colleau SM. The World Health Organization cancer pain and palliative care program, past, present, and future. J Pain Symptom Manag1996; 12: 65–72.
3.
McQuay H. Opioids in pain management. Lancet1999; 353: 2229–2232.
4.
Hanks G, Cherny N. Opioid analgesic therapy. In Doyle D, Hanks GWC, MacDonald N eds. Oxford textbook of palliative medicine, second edition. New York: Oxford University Press, 1998: 331–352.
5.
Expert Working Group of the European Association for Palliative Care. Fortnightly Review: morphine in cancer pain: models of administration. BMJ1996; 312: 823–826.
6.
Mercadante P, Fulfaro F, Casuccio A. Investigation of an opioid response categorization in advanced cancer patients. J Pain Symptom Manag1999; 18: 347–352.
7.
Mercadante S, Casuccio A, Pumo S, et al. Opioid responsiveness-primary diagnosis relationship in advanced cancer patients followed at home. J Pain Symptom Manag2000; 20: 27–34.
8.
Wolff T, Samuelsson H, Hender T. Concentrations of morphine and morphine metabolites in CSF and plasma during continuous subcutaneous morphine administration in cancer pain patients. Pain1999; 68: 209–216.
9.
Vermeire A, Remon JP, Rosseel MT, et al. Variability of morphine disposition during long-term subcutaneous infusion in terminally ill cancer patients. Eur J Clin Pharmacol1998; 53: 325–330.
10.
Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol1984; 2: 187–193.
11.
Konishi M, Hashimoto H. On-line clean-up system of plasma sample for simultaneous determination of morphine and its metabolites in cancer patients by high-performance liquid chromatography. J Pharmacol Sci1990; 79: 379–383.
12.
Faura CC, Moore RA, Horga JF, et al. Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain. J Pain Symptom Manag1996; 11: 95–102.
13.
Hanks GW, Hoskin PJ, Aherne GW, et al. Explanation for potency of repeated oral doses of morphine. Lancet1987; 26: 723–724.
14.
Stain F, Barjavel MJ, Sandouk P, et al. Analgesic response and plasma and brain extracellular fluid pharmacokinetics of morphine and morphine-6-beta-D-glucuronide in the rat. J Pharmacol Exp Ther1995; 274: 852–857.
15.
Krzanowska EK, Rossi GC, Pasternak GW, et al. Potency ratios of morphine and morphine-6 beta-glucuronide analgesia elicited from the periaqueductal gray, locus coeruleus or rostral ventromedial medulla of rats. Brain Res1998; 799: 329–333.
16.
Osborne R, Thompson P, Joel S, et al. The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol1992; 34: 130–138.
17.
Penson RT, Joel SP, Bakhshi K, et al. Randomized placebo-controlled trial of the activity of the morphine glucuronides. Clin Pharmacol Ther2000; 68: 667–676.
18.
Mercadante S. The role of morphine glucuronides in cancer pain. Palliat Med1999; 13: 95–104.
19.
Serlin RC, MendozaTR, Nakamura Y, et al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain1995; 61: 277–285.
20.
Cleeland CS, Nakamura Y, Mendoza TR, et al. Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scaling. Pain1996; 67: 267–273.
21.
Peterson GM, Randall CTC, Paterson J. Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration. Eur J Clin Pharmacol1990; 38: 121–124.
22.
Säve J, Svensson JO, Rane A. Morphine metabolism in cancer patients on increasing oral doses–no evidence for autoinduction or dose dependence. Br J Clin Pharmacol1998; 16: 85–93.
23.
Portenoy RK, Foley KM, Stulman J, et al. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain1991; 47: 13–19.
24.
Tiseo PJ, Thaler HT, Lapin J, et al. Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain1995; 61: 47–54.
25.
Patwardhan RV, Johnson RF, Hoyumpa A, et al. Normal metabolism of morphine in cirrhosis. Gastroenterology1981; 81: 1006–1011.
26.
Crotty B, Watson KJ, Desmond PV, et al. Hepatic extraction of morphine is impaired in cirrhosis. Eur J Clin Pharmacol1989; 36: 501–506.
